MCL1 and melanoma: Our studies demonstrated the efficacy of inhibiting both MCL1 and BCLXL in vitro and in vivo, and show that BH3 mimetics are potent at killing several hard to treat melanomas, including patient derived lines of diverse genetic backgrounds, rare subtypes of melanoma, and resistant or relapsed melanomas.